Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
15.79 USD | +2.87% | -.--% | -1.56% |
Summary
- On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
- From a short-term investment perspective, the company presents a deteriorated fundamental situation
Strengths
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
- Historically, the company has been releasing figures that are above expectations.
Weaknesses
- The company's enterprise value to sales, at 3.85 times its current sales, is high.
- For the last four months, the sales outlook for the coming years has been revised downwards. No recovery of the group's activities is yet foreseen.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-1.56% | 959M | C- | ||
+40.73% | 734B | C+ | ||
+32.83% | 591B | B | ||
-6.30% | 350B | C+ | ||
+15.15% | 315B | B- | ||
+4.05% | 276B | C+ | ||
+15.00% | 238B | B+ | ||
+9.78% | 206B | B- | ||
-5.52% | 204B | A+ | ||
+6.17% | 161B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- INVA Stock
- Ratings Innoviva, Inc.